<DOC>
	<DOCNO>NCT00647218</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving paclitaxel radiation therapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery . PURPOSE : This clinical trial study well give paclitaxel together radiation therapy work treat patient undergo surgery stage II stage III breast cancer .</brief_summary>
	<brief_title>Paclitaxel Radiation Therapy Treating Patients Undergoing Surgery Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate efficacy paclitaxel concurrent radiotherapy ( measure pathologic response rate ) patient stage II III breast cancer . Secondary - Evaluate toxicity treatment regimen . - Correlate paclitaxel-induced tumor response local recurrence-free survival , distant disease-free survival , overall survival . - Evaluate protein expression profile mass spectrometry biopsy material blood specimen collect treatment paclitaxel . OUTLINE : - Neoadjuvant chemotherapy : Patients receive paclitaxel IV 3 hour day 1 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . - Chemoradiotherapy : Beginning 3-4 week completion neoadjuvant chemotherapy , patient receive paclitaxel IV 1 hour twice weekly undergo radiotherapy daily , 5 day week , 6½ week . - Surgery : At 6-8 week completion chemoradiotherapy , patient undergo surgical resection ( e.g. , modified radical mastectomy lumpectomy axillary node dissection ) . - Adjuvant chemotherapy : Beginning 4-6 week surgery , patient receive doxorubicin hydrochloride IV 20 minute cyclophosphamide IV 1 hour day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Hormonal therapy : After completion adjuvant chemotherapy , patient estrogen receptor- and/or progesterone receptor-positive tumor receive hormonal therapy discretion treat physician . Patients undergo blood tissue sample collection periodically analyze change cell cycle flow cytometry ; antibody assay ; kinase assay cyclin B1/CDC2 ; genetic assay p53 , p21 , molecular marker ; protein expression assay mass spectrometry . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically document invasive carcinoma breast* Tumor ≥ 2 cm great dimension ( e.g. , T24 ) nodal status ( e.g. , N03 ) , include locally advanced disease , define follow criterion : Primary tumor ≥ 5 cm Tumor size direct extension chest wall skin Inflammatory breast cancer ( T4d ) Metastasis ipsilateral internal mammary node Ipsilateral lymph node clinically fix structure ( N2 ) NOTE : *Diagnosis may make core trucut biopsy Measurable evaluable tumor Measurable disease define mass reproducibly measure two perpendicular dimension Evaluable disease define lesion visible mammogram palpable physical exam fit criterion measurability Planning undergo breast conservation surgery Willing undergo AND candidate radiotherapy , judgement treat radiation oncologist No evidence distant metastatic disease ( e.g. , lung , liver , bone , brain ) Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 01 WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Left ventricular ejection fraction ≥ 45 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year , except curatively treat nonmelanomatous skin cancer carcinoma situ cervix No history hypersensitivity reaction product contain polysorbate 80 ( Tween 80 ) No serious medical illness , judgment treat physician , place patient risk No peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : Prior tamoxifen chemoprevention allow No prior radiotherapy ipsilateral breast Prior radiotherapy contralateral breast allow No prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>